Abstract There is increasing evidence for the role of chronic antigenic stimulation (CS) in the development of cancer. Clinical data, however, are rare as is the information on outcome. In this study, the occurrence of chronic infections (CI) and autoimmune diseases (AI) in patients with malignant lymphoma at diagnosis was assessed. Of 367 patients [non-Hodgkin´s lymphoma (NHL) N=297, Hodgkin´s lymphoma N=70], 9.8% (N=36) had a history of chronic antigenic stimulation (4.4% AI, 5.4% CI) at diagnosis. After a median observation time of 74.7 months, 118 patients have died. There were more male patients in this cohort. However, sex ratio among patients with chronic antigenic stimulation was skewed in favor of women (p= 0.018), in particular among lymphoma patients with AI (p= 0.001). NHL patients with autoimmune diseases showed a tendency to develop diffuse large B cell lymphoma [8 of 12 AI + NHL patients (66.7%) vs. 100 of 266 non-CS NHL (37.6%); p=0.066]. No significant difference in overall survival (OS) between CS and non-CS patients could be observed (median OS after 48 months was: CS 77.7% vs. non-CS 71.8%). In conclusion, chronic antigenic stimulation at diagnosis appears to be associated with a higher prevalence in women, in particular among patients with autoimmune disease. However, no difference in overall survival was observed. This suggests that the presence of chronic inflammatory conditions does not decisively influence the outcome of lymphoma patients.
Introduction
Malignant lymphomas are neoplasms of the lymphoid system characterized by a wide range of biological, pathological, and epidemiological features, thus showing heterogeneous clinical presentation and behavior [1] . Two major groups of malignancies can be distinguished, Hodgkin´s lymphoma (HL) and non-Hodgkin´s lymphomas (NHL). Incidences are 3/100,000 for HL and 10/100,000 for NHL per year in western countries, respectively, both subgroups have a male predominance (1.5-2:1) [2] , and the number of incidences is increasing [3] . The etiology of lymphomas is largely unknown. However, development may be accompanied by altered immunological functions, either chronic antigenic stimulation (CS) [chronic infections (CI), autoimmune disease (AI)] or immunosuppression (immunodeficiencies, transplant patients) [3, 4] . In particular, autoimmune diseases have repeatedly been shown to confer an increased risk for certain hematologic malignancies [5, 6] .
Linking infectious agents with neoplasia, however, is a more difficult task. To demonstrate a causal relationship between a microorganism and the development of a disease, certain criteria have to be fulfilled [7, 8] . Thus, Epstein-Barr virus (EBV), human herpes virus 8, human T-lymph tropic virus type I, human immunodeficiency virus, Plasmodium falciparum, hepatitis C virus (HCV), hepatitis B virus (HBV), Helicobacter pylori (HP), Campylobacter jejuni, Chlamydia psittaci, and Borrelia burgdorferi have been shown to be associated with malignant lymphoma (reviewed by Hjalgrim [9] ). The common theme in these settings is a state of persistent foreign-or auto-antigenic stimulation initiating inflammatory responses. The accelerated expansion of particular cell populations involves an increased risk for genetic lesions and/or functional errors which may perturb balance and interactions of immune cell compartments. Accumulation of additional transforming events may then trigger malignant progression of lymphoid clones leading to lymphoma or leukemia (see also Fisher & Fisher [10] ).
Considering the tight association of AI and CI with hematologic malignancies, surprisingly few data are available regarding the prevalence of CS in lymphoma patients. Also, it is still largely unclear how and to which degree CS influences the course of the disease in terms of prognosis and treatment. Therefore, we investigated the occurrence of chronic infectious and autoimmune diseases in patients with malignant lymphoma. These data were correlated with age, sex, type of disease, the international prognostic index (IPI) for NHL, and overall survival (OS).
Materials and methods

Patients
This is a retrospective, monocentric study performed at the Division of Hematology and Hemostaseology of the Medical University of Vienna. In total, 574 patients with malignant lymphoma were diagnosed at the unit between 2001 and 2005. Of note, this number does not include patients with chronic lymphocytic leukemia (CLL) and mucosa-associated lymphoid tissue (MALT) lymphoma since results for these entities were published elsewhere [11, 12] . Of 574 patients, 94 were excluded from the analysis because of underlying immunosuppression (HIV positivity, posttransplant lymphoproliferative disorder, common variable immunodeficiency) or because they had primary CNS lymphomas. Of the remaining 480 patients, 386 suffered from Non-Hodgkin´s and 94 from Hodgkin´s lymphoma. Due to insufficient survival data, the number of patients was reduced to 297 and 70 for NHL and HL, respectively. Thus, a total of 367 patient records were analyzed for this study.
Patients were considered having chronic conditions only if specific medical records or laboratory data or both were available. Patient data collected included: sex, age, mortality, lymphoma subtype, international prognostic index, and treatment. Lymphomas studied were diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), T-cell neoplasms (PTCL-peripheral T-cell lymphoma; T-ALCL-T-cell anaplastic large cell lymphoma, T-LGL-T-cell large granular lymphocytic leukemia), marginal zone lymphoma (MZL; splenic and nodal subtypes), small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), and unclassifiable B-cell lymphoma with features intermediate between DLBCL and Burkitt lymphoma (ICD-O code 9680/3 [13] ). Rare subtypes and unspecified types of lymphomas were combined as "other B cell lymphomas". DLBCL, FL grade 3, high grade unclassifiable B-cell lymphoma, PTCL, and T-ALCL were defined as aggressive, the remaining malignancies as indolent lymphoma subtypes. Chronic infections were defined as chronic or recurrent conditions caused by an infectious agent at least 6 months prior to lymphoma diagnosis and included: chronic colitis, EBV, HCV, HBV, HP gastritis, lues latens (Treponema infection), and chronic respiratory tract infections (RTI). Autoimmune diseases included were: systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Hashimoto's thyroiditis (HT), ulcerative colitis (UC), urticarial vasculitis, idiopathic thrombocytopenic purpura (ITP), Sjögren's syndrome, and atopic dermatitis. Patients received standard chemotherapeutic lymphoma treatment including CD20 antibody therapy or radiation according to guidelines and current clinical practice.
Statistical analysis
Categorical variables were described by absolute and relative frequencies and compared between groups using chi-square tests (or Fisher´s exact tests where necessary). Age was described by median and range due to its skewed distribution and compared between groups using Wilcoxon´s rank-sum test. Overall survival was calculated from the time of diagnosis either until death or date last seen at the clinic and is represented graphically based on Kaplan-Meier estimates. Median observation time was estimated using the inverse Kaplan-Meier method [14] . In order to quantify the potential effect of various factors on overall survival, a multi-variable Cox proportionalhazards model was used. The independent variables in this model comprise CS vs. non-CS, NHL vs. HL, AI vs. CI, and gender. Furthermore, a variable was nested in the NHL group in order to distinguish aggressive from indolent lymphoma. Since this variable showed a timedependent effect on overall survival, its interaction with log-time was also nested in the NHL group. No other interaction of CS vs. non-CS was significant, thus the CS effect is the same for NHL and HL as well as for both sexes.
In order to evaluate the influence of incorporating IPI classification on the results of survival analysis, a three-stage classification variable was used as stratification factor in a Cox model on a reduced data set. For this purpose, patients suffering from DLBCL and FL (N=180; data available for 141 patients) were classified into low, intermediate, and high risk groups (IPI 0-1 = low risk, IPI 2-3 = intermediate risk, IPI 4-5 = high risk) before the model was applied. Due to the low number of CS patients, DLBCL and FL were analyzed together (N=23).
The reported p values are the results of two-sided tests. P values≤0.05 were considered to be statistically significant. All computations have been performed using SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA, 2008)
Results
General considerations
In this study, 367 patients with malignant lymphoma were analyzed regarding a history of chronic antigenic stimulation. Of these patients, 70 suffered from HL. Patients with NHL (N=297) had diffuse large B cell lymphoma (N=115), follicular lymphoma (N=65), mantle cell lymphoma (N=21), T-cell neoplasms (N=19), marginal zone lymphoma (N=18), small lymphocytic lymphoma (N=14), lymphoplasmacytic lymphoma (N=9), Burkitt-like lymphoma (N=1), and other lymphomas (N=35). A history of chronic antigenic stimulation was found in 36 patients (9.8%), 16 with AI (4.4%), and 20 with CI (5.4%) ( Tables 1 and 2 ). AI diseases found were SLE (N=4; 1.1%), Hashimoto´s thyroiditis (N=3; 0.8%), RA (N=3; 0.8%), ulcerative colitis (N=2; 0.5%), atopic dermatitis (N=1; 0.3%), ITP (N=1; 0.3%), Sjögren´s syndrome (N=1; 0.3%), and urticarial vasculitis (N=1; 0.3%). CI included respiratory tract infections (N=6; 1.6%), HCV (N=5; 1.4%), HBV (N=3; 0.8%), HP gastritis (N=3; 0.8%), chronic colitis (N=1; 0.3%), EBV (N=1; 0.3%), and lues latens (N=1; 0.3%). One HL patient with RA had concomitant RTI. This patient was classified under AI because in our opinion, AI outweighs CI. CS diseases as found per lymphoma subtype are listed in Tables 1 and 2 . One hundred eighteen patients have died, the median observation period was 74.7 months (quartiles: 62.6 to 89.1 months). No significant difference in overall survival between CS and non-CS patients was observed (HR 0.63, 95% confidence interval 0.26-1.54; p= 0.311). Kaplan-Meier estimates for survival after 48 months were 77.7% in CS vs. 71.8% in non-CS patients (HL: CS 100.0%, non-CS 88.7%; aggressive NHL: CS 66.7%, non-CS 58.6%; indolent NHL: CS 84.6%, non-CS 77.0%; p=0.311). Patient characteristics are listed in Table 3 . Median age at diagnosis of lymphoma was 57.0 years for CS patients and 59.7 years for non-CS patients (p=0.775).
Sex-specific differences
We found a slight male predominance in this patient cohort, men constituting 51.7% (N=190) of patients compared to 48.2% women (N=177). Considering CS patients only, however, there was a significant prevalence of women (66.7% or N=24) compared to the non-CS group (45.9% or N=152) (p=0.018) which was due to an overrepresentation of women in the AI group (87.5%; N=14) (p=0.001). In the CI group, no gender bias was found (50% women; N= 10; p=0.851). The effect of CS vs. non-CS on OS was the same in both sexes (p=0.249)
NHL-antigenic stimulation
Twelve patients with NHL had a history of AI, 19 showed CI. This corresponds to 4.1% and 6.4% of 297 NHL patients, respectively. Most frequent AI were SLE (N=4; 1.35%) and HT (N=2; 0.67%). Among CI, RTI (N=6; 2.02%) ranked top followed by HCV (N=5; 1.68%), HBV (N=3; 1.01%), and HP (N=3; 1.01%). For a complete list see Table 1 .
Considering NHL subtypes, 58.1% (N =18) of CS patients suffered from an aggressive lymphoma of B-cell type compared to 51.1% (N=133) of patients without antigenic stimulation (p=0.395). Among AI patients only, the prevalence of an aggressive subtype was 75% (N=9 of 12), among CI patients 9 of 19 had aggressive lymphomas (47.4%). DLBCL was slightly more prevalent in the CS group than in the non-CS group (48.4% vs. 37.6%) (p= 0.243). Among CS patients, notably persons suffering from autoimmune diseases showed a high rate of DLBCL (66.7% vs. 37.6% of non-CS patients) (p=0.066). The effect of CS on OS was not significantly different, being the same in indolent and aggressive lymphomas (HR=0.63, p= 0.311) (Fig. 1) .
Additional lymphomas found in the CS group were: FL (N=8; 26%), MCL (N=4; 13%), MZL (N=2; 6%), and other B cell lymphomas (N=2; 6%). Of note, MCL and MZL cases were associated with CI only. In the case of MZL, the low number may be explained by the fact that MALT lymphomas were not included in this study. Among SLL, T-cell neoplasms (PTCL, T-ALCL, T-LGL) and LPL, no history of AI or CI was found. Median age at NHL diagnosis was lower in CS patients (60.1 vs. 62.4 years; p=0.203).
To include prognostic markers in the model, patients with the most frequent histologies, DLBCL and FL, were risk stratified based on the international prognostic index. Abbreviations: see Table 1 Abbreviations: CS chronic antigenic stimulation, AD atopic dermatitis, AI autoimmune disease, CC chronic colitis, CI chronic infection, FL follicular lymphoma, DLBCL diffuse large B cell lymphoma, EBV Epstein-Barr virus, HCV hepatitis C virus, HBV hepatitis B virus, HL Hodgkinś Lymphoma, HT Hashimoto´s thyroiditis, ITP immune thrombocytopenia, LL lues latens, LPL lymphoplasmacytic lymphoma /Morbus Waldenström, MCL mantle cell lymphoma, MZL marginal zone lymphoma (splenic and nodal types), N number of patients, RA rheumatoid arthritis, RTI respiratory tract infections, SLE systemic lupus erythematosus, SS Sjögren´s syndrome, T-cell neoplasms: PTCL peripheral T-cell lymphoma, T-ALCL T-cell anaplastic large cell lymphoma, T-LGL T-cell large granular lymphocytic leukemia, UC ulcerative colitis, UV urticarial vasculitis (N=21 vs. 10; 67.7% vs. 32.3%) (p=0.021). Sex had no significant influence on OS (p=0.072), albeit men had a slightly better OS than women (HR 0.71, 95% confidence intervals 0.50-1.03). Interestingly, CS men showed the best OS compared to all other groups. Non-CS men and CS and non-CS women had comparable OS (Fig. 2) . However, the effect of CS vs. non-CS on OS was not significantly different for the two sexes, being thus in both genders HR= 0.63 (p=0.311).
HL-antigenic stimulation
Five patients out of 70 persons with HL (7.1%) were found to have a history of CS, 4 with AI (5.6%) and 1 with CI Abbreviations: CS chronic antigenic stimulation, AI autoimmune disease, CI chronic infection, DLBCL diffuse large B cell lymphoma, HL Hodgkin´s lymphoma, LPL lymphoplasmacytic lymphoma /Morbus Waldenström, NHL non-Hodgkin´s lymphoma, SLL small lymphocytic lymphoma, N number of patients, ND not determined Fig. 1 Overall survival of NHL patients with indolent or aggressive lymphoma subtype in relation to a history of chronic stimulation (N=297). The effect of CS on OS was not significantly different in indolent and aggressive lymphomas (p=0.311) Fig. 2 Overall survival of NHL patients in relation to sex and chronic stimulation (N=297).
(Male vs. female p=0.072; CS vs. non-CS p=0.311 in both men and women) (1.4%) ( Table 2 ). Chronic diseases found were RA (N=2; 2.8%), HT (N=1; 1.4%), and UC (N=1; 1.4%). The single patient with CI had EBV infection (1.4%). Histological data on LMP1 expression were available for 32/70 patients, 31 were negative, a single patient was LMP1 positive. As in NHL, CS conferred a slight advantage for OS in HL patients (OR 0.63, 95% confidence intervals 0.26-1.54, p= 0.311). Median age at diagnosis was 53.1 years for CS patients and 34.5 years for non-CS patients (p=0.454).
HL-sex-specific differences Sex distribution of the entire cohort were 51.4% men and 48.5% women (N=36 vs. N=34). The CS group consisted of three women and two men (60% vs. 40%), within the non-CS group, women constituted 48% (N=31), men 52% (N=34).
Discussion
Chronic antigenic stimulation has long been implicated in the development of non-HIV associated hematologic malignancies. Reasons are the observed prevalence and the increased risk of cancer particularly among patients with autoimmune diseases and the association of some infectious agents with certain malignancies. In this study, we found a prevalence of 9.8% for a history of chronic stimulation in a cohort of 367 malignant lymphoma patients, rates being almost equal for AI and CI. Published estimates of AI prevalence in the general population range between 3% and 10% [15] [16] [17] and was reported to lie between 5% and 8% within the US population [18] . The prevalence of 4.4% of AI in our study cohort, thus, is in concordance with these reports for western countries. Only for SLE, a higher prevalence was observed compared to the general population (1.1% vs. 0.02-0.04%) [17, 19] . The prevalence of 4% AI among our NHL patients, however, was lower compared to a study published by Cuttner who found 13% of NHL patients to have a history of AI compared to 5% of controls [20] . Of note, Cuttner and colleagues analyzed HL and CLL patients with the control group. Other studies reported 39% AI among MALT lymphoma patients [11] , and 16% and 11.8%, respectively, in CLL [12, 21] . In all three studies, AI patients with malignant diseases were predominantly women.
According to the Austrian Ministry of Health, the prevalence of HCV in Austria is 0.7% and that of HBV is even lower. In this study cohort, HCV and HBV constituted 1.4% (N=5) and 0.8% (N=3) of patients, respectively, which would indicate a twofold overrepresentation compared to the general population. On the other hand, conflicting results have been obtained regarding the frequency of such infections among lymphoma patients from other countries. Some studies found no association of HCV or HBV infections with NHL [22] [23] [24] , other studies found a higher prevalence of hepatitis C and B in NHL patients compared to controls [25] [26] [27] . This has, in part, been ascribed to different rates of hepatitis infections in the general population of the respective countries. Wang reported a decreased rate of HBV infections in patients with T-cell lymphoma compared to patients with B-cell malignancies [28] .
In our study, SLL and T-cell lymphoma patients were not found to have a history of chronic stimulation, neither did LPL patients. This probably is due to the low patient numbers for these disease entities and the low prevalence of AI in general.
Considering the entire patient cohort, men were only slightly overrepresented compared to women (52% vs. 48%), and this distribution of sexes did not change when analyzing NHL and HL separately. However, among CS patients women predominated which was due to an overrepresentation of women in the AI group (87.5%). Due to few CS patients, this difference was not statistically significant in HL.
Median age at diagnosis of CS and non-CS patients was not statistically different in any of the groups. While among NHL patients non-CS patients were slightly older, the reverse was observed in HL patients where non-CS patients were much younger than CS patients. HL is known to have a bimodal distribution, one peak at an age of about 30 years and a second peak at 50 years and older [9] , the most striking difference being that HL in young adults is less likely associated with EBV compared to the older age group [29] . The results here are in concordance with the reported distribution of HL in developed countries, where etiological agents responsible for HL incidence in the young adult age group remain to be elucidated [29] . Still, it is notable that only 1 of 70 HL patients had concomitant clinical EBV infection, the other CS patients suffering from autoimmune disorders.
While CS patients were more often found to have an aggressive type of lymphoma, there was no significant difference in overall survival between CS and non-CS patients. The same was observed in indolent and aggressive subtypes and in both sexes. To assess for an association with known prognostic markers, DLBCL and FL patients were risk classified according to the IPI and the data incorporated in the Cox model. Even after stratification, no significant deviations from the original model could be observed indicating a lack of prognostic relevance.
This study has some limitations. Rigid criteria were used with regard to classifying a patient as CS or non-CS. Due to missing laboratory data, the number of CS patients may be underestimated, and serological evidence was not obtained in all patients. Thus, confidence is placed in the diagnosing physician and in the data provided by the patient during the interview. Since chronic infections, particularly RTI, might be due to immunosuppression caused by lymphomagenesis, in some cases it will remain unclear whether CI was preexisting or a result of the developing lymphoma. The prevalence of chronic antigenic stimulation may also be under-or overestimated due to this study not being a casecontrol study.
The major conclusion of this study is that the presence of chronic antigenic stimulation in general does not decisively influence the clinical outcome of lymphoma patients. This does not preclude that in some cases additional specific antiinflammatory or anti-infectious treatment may be required.
